It is noteworthy that the interest in developing pharmacological agents capable of converting meals into low GI meals, i.e., alpha-glucosidase inhibitors (acarbose and voglibose), reinforces the importance of low GI as a means of reducing the risk of T2DM and accompanying diseases by improving glycemic control and post-load insulin levels (54, 55). This evidence concerns the gene INS and type 2 diabetes mellitus.